FDA warned MYA International that its supplement and herbal product labels made unapproved drug claims and its dietary supplements violated manufacturing quality and labeling rules.
What happened
FDA inspected MYA International’s Chula Vista, CA facility on 8/30/2021-9/3/2021, 9/8/2021, and 9/10/2021 and reviewed product labeling collected during the inspection. FDA found that catalog claims for Hygly, Diapro-Z, Bioampixilina, Penalin, Colloidal Silver, Tea, Quiebra Piedras, Shark Cartilage, and Helper said the products treat diseases such as diabetes, infections, cancer, and Parkinson’s-like memory problems, making them unapproved new drugs. The inspection also found dietary supplement current good manufacturing practice (CGMP) violations, including missing specifications and incomplete batch production records, and labeling violations.
What FDA found
The products are unapproved new drugs because their labels claim they cure, mitigate, treat, or prevent diseases, and FDA has not approved them for those uses.
sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]The products are misbranded drugs because they lack adequate directions for use by a layperson for their intended disease uses.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]The company did not set finished-batch specifications for identity, purity, strength, composition, and contamination limits.
21 CFR 111.70(e)The company did not set component specifications or verify component identity, and it did not qualify suppliers whose certificates of analysis it relied on.
21 CFR 111.70(b), 111.75(a)(1)(i), 111.75(a)(2)The company did not prepare batch production records for every batch, and some records were blank, unsigned, or undated.
21 CFR 111.255(a), 111.255(b), 111.260The company did not identify all processing lines and major equipment; FDA saw an unidentified brown powder in a capsule machine hopper.
21 CFR 111.365(k)
What FDA wants
FDA tells MYA International to correct the cited unapproved-drug, CGMP, and labeling violations, including establishing product and component specifications, completing batch records, identifying equipment, and fixing labels. The provided letter text does not state a response deadline.
Who should pay attention
- retailers and distributors selling MYA International supplements
- companies using MYA International as a supplement manufacturer or supplier
- quality teams handling dietary supplement CGMP and label claims
This is a summary. Read the original letter on fda.gov.